MedTrace Logo

tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

NCT05360264 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-03-24

No results posted yet for this study

Summary

The study is designed to assess the therapeutic efficacy of decitabine repurposing against advanced, refractory, ductal adenocarcinoma (PDAC) with molecular transcriptional signatures indicating dependency on the KRAS oncogene

Conditions

  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma Recurrent

Interventions

DRUG

Decitabine 50 MG [Dacogen]

DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.

Sponsors & Collaborators

  • Anticancer Fund, Belgium

    collaborator OTHER

  • Azienda Ospedaliera Universitaria Integrata Verona

    collaborator OTHER

  • Catholic University of the Sacred Heart

    collaborator OTHER

  • Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

    collaborator NETWORK

  • San Raffaele University Hospital, Italy

    collaborator OTHER

  • University of Pisa

    collaborator OTHER

  • Luca Cardone

    lead OTHER

Principal Investigators

  • LUCA CARDONE, PhD · ISTITUTI FISIOTERAPICI OSPITALIERI- IFO - ISTITUTO REGINA ELENA

  • Michele Milella, Prof. · AZ.OSP.UNIVERSITARIA INTEGRATA VERONA- BORGO ROMA 05091202

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2024-10-10
Completion
2024-10-10
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360264 on ClinicalTrials.gov